The impact of polymorphism in PNPLA3 and TM6SF2 genes on the susceptibility and survival of hepatitis C-related hepatocellular carcinoma

Egyptian Liver Journal

Table 2 Genotype distribution of PNPLA3 rs738409 and TM6SF2 rs58542926 in HCV and HCC patients

		HCV N=144	HCC N=120	^aP value	OR	95% C.I	^bP value
PNPLA3 rs738409	CC	72 (50.0%)	57 (47.5%)	0.6	1 (reference)
	CG	58 (40.3%)	48 (40.0%)	0.9	1.045	0.624–1.753	0.8
	GG	14 (9.7%)	15 (12.5%)	0.4	1.353	0.604–3.033	0.4
	C Allele	202 (0.701)	162 (0.675)	0.6	1 (reference)
	G Allele	86 (0.299)	78 (0.325)	0.6	1.131	0.781–1.637	0.5
TM6SF2 rs58542926	CC	107 (74.3%)	84 (70.0%)	0.3	1 (reference)
	CT	35 (24.3%)	28 (23.3%)	0.8	1.019	0.574–1.808	0.9
	TT	2 (1.4%)	8 (6.7%)	0.03*	5.095	1.054–24.629	0.04*
	C Allele	249 (0.865)	196 (0.817)	0.2	1 (reference)
	T Allele	39 (0.135)	44 (0.183)	0.2	1.433	0.896–2.293	0.1

OR Odds ratio, CI Confidence interval; ^*P value ≤ 0.05 significant; ^**P value ≤ 0.01 highly significant. ^aP value is depending on the X² test, while ^bP value is depending on the logistic regression analysis